LNJ

Pharmaceutical preparations for the treatment of brain disease using technology capable of passing through the blood-brain barrier (BBB) to deliver therapeutic proteins directly to brain tissue, using the DAT (dual action therapy) platform for medical purposes; pharmaceutical preparations for the treatment of Alzheimer's disease (senile dementia); pharmaceutical preparations for the treatment of brain disease for medical purposes; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of neurodegenerative brain diseases for medical purposes; pharmaceutical preparations for the treatment of Parkinson's disease.

Conducting clinical trials in the field of brain, central nervous system diseases; research and development of vaccines and medicines; development of cell therapy products; drug discovery services; scientific research for medical purposes in the area of cancerous diseases; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research laboratory services for predicting disease; medical research laboratory services in the field of the blood-brain barrier (BBB); medical research laboratory services in the field of Alzheimer's disease.